Allergic rhinitis and asthma in children: Disease management and outcomes
- 49 Downloads
Antihistamines and inhaled glucocorticoids, which can be targeted toward multiple points in the "allergic cascade" underlying allergic rhinitis and asthma, extend the promise of enhanced outcomes in children with allergic rhinitis, asthma, or both. Antihistamine therapy confers significant relief of subjective ratings of seasonal and perennial allergic symptoms (eg, rhinorrhea, congestion, sneezing, pruritus), whereas topical steroids alleviate such discomfort while also improving objective anatomic and functional indices of nasal patency (eg, nasal peak inspiratory flow). Youngsters with asthma also experience substantial clinical benefits from inhaled steroids, which improve objective measures of pulmonary function and reduce rescue b2-agonists for symptom management and quality-of-life enhancement. This paper reviews recent clinical findings on the role of antihistamines and topical corticosteroids in pediatric allergy and asthma management, as well as the favorable effects of these medications on both objective and subjective health outcomes.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 8.John M, Lim S, Seybold J, et al.: Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 1998, 157:256–262.PubMedGoogle Scholar
- 11.Pearlman DS, Lumry WR, Winder JA, Noonan MJ: Once-daily cetirizine effective in the treatment of seasonal allergic rhinitis in children aged 6 to 11 years: a randomized, doubleblind, placebo-controlled study. Clin Pediatr (Phila) 1997, 36:209–215.Over a 4-week treatment interval, once-daily therapy with cetirizine at 10 mg significantly reduced total and individual rhinitis symptom scores, including ocular itching and oral/nasal itching, from baseline in 209 children aged 6 to 11 with seasonal allergic rhinitis. As compared with placebo, a lower cetirizine dose (5 mg/day) did not decrease symptoms from baseline.CrossRefGoogle Scholar
- 19.The Childhood Asthma Management Program Research Group:Long-term effects of budesonide or nedocromil in children with asthma. N Engl J Med 2000, 343:1054–1063.This long-term, placebo-controlled follow-up study involving 1041 children with mild to moderate asthma demonstrated that budesonide therapy (200 ώg bid) significantly diminished hospitalizations, urgent caregiver visits, and albuterol use from baseline while increasing proportions of episode-free days and exhibiting an oral steroidsparing effect as compared with placebo. Although changes in most postbronchodilator spirometric variables were not different in budesonide-treated patients as compared with a control group, therapy with the inhaled corticosteroid did significantly attenuate airway responsiveness to methacholine.CrossRefGoogle Scholar
- 23.Henriksen JM, Dahl R: Effects of inhaled budesonide alone and in combination with low-dose terbutaline in children with exercise-induced asthma. Am Rev Respir Disease 1983, 128:993–997.Google Scholar
- 36.Mahajan P, Pearlman D, Okamoto L: The effect of fluticasone propionate on functional status and sleep in children with asthma and on the quality of life of their parents. J Allergy Clin Immunol 1998, 102:19–23.Long-term therapy with inhaled fluticasone propionate (50 to 100 ώg twice daily) for 24 to 52 weeks not only significantly enhanced quality of life and functional status of children with mild to moderate asthma, diminishing sleep disturbances; consistent with these findings, parents of actively treated children (vs controls) also reported a significantly lower burden on a quality-of-life instrument.PubMedCrossRefGoogle Scholar
- 38.Global Initiative for Asthma: Global strategy for asthma management and prevention report. Bethesda, MD: National Institutes of Health; 1995. [NIH publication no. 96-3659A, NHLBI].Google Scholar
- 39.Rabe KF, Vermeire PA, Soriano JB, Maier WC: Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000, 16:802–807.Although consensus guidelines for the treatment of moderate to severe or persistent asthma in children warrant the use of medications that attenuate or reverse inflammation, this Western European household survey determined that most respondents had used prescription "quick-relief" medications (63%) rather than inhaled corticosteroids (23%). By either objective (eg, lung function) or subjective (eg, symptom control) standards, the data suggested that current asthma care falls decidedly short of consensus goals.PubMedCrossRefGoogle Scholar